drugset / Trial / NCT05007262

Tangningtongluo Tablet in the Treatment of Non-proliferative Diabetic Retinopathy

NCT05007262 ↗

Phase 2 Unknown 240 enrolled Guizhou Bailing Group Pharmaceutical Co Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is planned to collect relevant clinical data to evaluate the prevention efficacy and safety of Tangningtongluo tablets on the non-proliferation period of diabetic retinopathy.

Timeline

Start
2021-08-31
Primary completion
2023-10-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcium dobesilate capsules Unknown — Oral
Subject Tangningtongluo tablets Unknown — Oral